{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:23:24Z","timestamp":1728361404616},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,7]]},"DOI":"10.7759\/cureus.71019","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T18:15:23Z","timestamp":1728324923000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Intersection of Atypical Hemolytic Uremic Syndrome and Substance Use: A Comprehensive Narrative Review"],"prefix":"10.7759","author":[{"given":"Abrisham","family":"Akbariansaravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anushka","family":"Dekhne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archi","family":"Dhamelia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mekhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01646-4","article-title":"Atypical HUS with multiple complement system mutations triggered by synthetic psychoactive drug abuse: a case report","volume":"36","author":"Jelicic I","year":"2023","unstructured":"Jelicic I, Kovacic V, Luketin M, Mikacic M, Skaro DB. Atypical HUS with multiple complement system mutations triggered by synthetic psychoactive drug abuse: a case report. J Nephrol. 2023, 36:2371-3. 10.1007\/s40620-023-01646-4","journal-title":"J Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review","volume":"12","author":"Yan K","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020, 12:295-305. 10.2147\/CLEP.S245642","journal-title":"Clin Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina R","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019, 23:4-21. 10.1111\/1744-9987.12763","journal-title":"Ther Apher Dial"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/9781119105954.ch26","article-title":"Hemolytic uremic syndrome","author":"Lebel A","year":"2022","unstructured":"Lebel A, Kirpalani A, Licht C. Hemolytic uremic syndrome. Evidence\u2010Based Nephrology, Second Edition. Craig JC, Molony DA, Strippoli GFM (ed): Wiley, Hoboken, NJ; 2022. 425-43. 10.1002\/9781119105954.ch26"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.22038\/APJMT.2021.18818","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: rare manifestations of Russell\u2019s viper (Daboia russelii) envenoming in Sri Lanka","volume":"10","author":"Rathnayaka RMMK","year":"2021","unstructured":"Rathnayaka RMMK, Ranathunga PEAN, Kularatne SAM. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: rare manifestations of Russell\u2019s viper (Daboia russelii) envenoming in Sri Lanka. Asia Pac J Med Toxicol. 2021, 10:117-23. 10.22038\/APJMT.2021.18818","journal-title":"Asia Pac J Med Toxicol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010039","article-title":"The role of the complement system in the pathogenesis of infectious forms of hemolytic uremic syndrome","volume":"14","author":"Avdonin PP","year":"2024","unstructured":"Avdonin PP, Blinova MS, Generalova GA, Emirova KM, Avdonin PV. The role of the complement system in the pathogenesis of infectious forms of hemolytic uremic syndrome. Biomolecules. 2024, 14:39. 10.3390\/biom14010039","journal-title":"Biomolecules"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri F","year":"2021","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021, 17:543-53. 10.1038\/s41581-021-00424-4","journal-title":"Nat Rev Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/370426","article-title":"Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects","volume":"2012","author":"Bu F","year":"2012","unstructured":"Bu F, Borsa N, Gianluigi A, Smith RJ. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol. 2012, 2012:370426. 10.1155\/2012\/370426","journal-title":"Clin Dev Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris M","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009, 361:1676-87. 10.1056\/NEJMra0902814","journal-title":"N Engl J Med"},{"key":"ref10","article-title":"Genetic atypical hemolytic-uremic syndrome","author":"Noris M","year":"2021","unstructured":"Noris M, Bresin E, Mele C, Remuzzi G. Genetic atypical hemolytic-uremic syndrome. GeneReviews\u00ae. Adam MP, Feldman J, Mirzaa GM, et al. (ed): University of Washington, Seattle, WA; 2021."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0000000000000079","article-title":"2014 combined annual meeting abstracts","volume":"62","author":"Sphingosine PO","year":"2014","unstructured":"Sphingosine PO. 2014 combined annual meeting abstracts. J Investig Med. 2014, 62:703. 10.2310\/JIM.0000000000000079","journal-title":"J Investig Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151436","article-title":"HUS and TTP: traversing the disease and the age spectrum","volume":"43","author":"Donadelli R","year":"2023","unstructured":"Donadelli R, Sinha A, Bagga A, Noris M, Remuzzi G. HUS and TTP: traversing the disease and the age spectrum. Semin Nephrol. 2023, 43:151436. 10.1016\/j.semnephrol.2023.151436","journal-title":"Semin Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040304","article-title":"Compound haplotype variants in CFH and CD46 genes determine clinical outcome of atypical hemolytic uremic syndrome (aHUS)\u2014a series of cases from a single family","volume":"11","author":"Furma\u0144czyk-Zawiska A","year":"2021","unstructured":"Furma\u0144czyk-Zawiska A, Kubiak-Dydo A, U\u017carowska-G\u0105ska E, et al.. Compound haplotype variants in CFH and CD46 genes determine clinical outcome of atypical hemolytic uremic syndrome (aHUS)\u2014a series of cases from a single family. J Pers Med. 2021, 11:304. 10.3390\/jpm11040304","journal-title":"J Pers Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914496","article-title":"Underlying genetics of aHUS: which connection with outcome and treatment discontinuation?","volume":"24","author":"Spasiano A","year":"2023","unstructured":"Spasiano A, Palazzetti D, Dimartino L, Bruno F, Baccaro R, Pesce F, Grandaliano G. Underlying genetics of aHUS: which connection with outcome and treatment discontinuation?. Int J Mol Sci. 2023, 24:14496. 10.3390\/ijms241914496","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-815499-1.00023-5","article-title":"Chapter 23 - The complement system","author":"Willrich MAV","year":"2020","unstructured":"Willrich MAV. Chapter 23 - The complement system. Contemporary Practice in Clinical Chemistry, Fourth Edition. Clarke W, Marzinke MA (ed): Academic Press, Cambridge, MA; 2020. 391-412. 10.1016\/B978-0-12-815499-1.00023-5"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981375","article-title":"The role of the complement system in kidney glomerular capillary thrombosis","volume":"13","author":"Yoshida Y","year":"2022","unstructured":"Yoshida Y, Nishi H. The role of the complement system in kidney glomerular capillary thrombosis. Front Immunol. 2022, 13:981375. 10.3389\/fimmu.2022.981375","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.811504","article-title":"Complement mediated endothelial damage in thrombotic microangiopathies","volume":"9","author":"Blasco M","year":"2022","unstructured":"Blasco M, Guill\u00e9n-Olmos E, Diaz-Ricart M, Palomo M. Complement mediated endothelial damage in thrombotic microangiopathies. Front Med (Lausanne). 2022, 9:811504. 10.3389\/fmed.2022.811504","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01547-y","article-title":"Immunologic and genetic contributors to CD46-dependent immune dysregulation","volume":"43","author":"Meyer BJ","year":"2023","unstructured":"Meyer BJ, Kunz N, Seki S, et al.. Immunologic and genetic contributors to CD46-dependent immune dysregulation. J Clin Immunol. 2023, 43:1840-56. 10.1007\/s10875-023-01547-y","journal-title":"J Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-015-2642-1","article-title":"Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network","volume":"175","author":"Ardissino G","year":"2016","unstructured":"Ardissino G, Salardi S, Colombo E, et al.. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr. 2016, 175:465-73. 10.1007\/s00431-015-2642-1","journal-title":"Eur J Pediatr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey MA","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, et al.. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010, 21:2180-7. 10.1681\/ASN.2010030315","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.06.048","article-title":"Bloody diarrhea and Shiga toxin-producing Escherichia coli hemolytic uremic syndrome in children: data from the ItalKid-HUS Network","volume":"237","author":"Ardissino G","year":"2021","unstructured":"Ardissino G, Vignati C, Masia C, et al.. Bloody diarrhea and Shiga toxin-producing Escherichia coli hemolytic uremic syndrome in children: data from the ItalKid-HUS Network. J Pediatr. 2021, 237:34-40.e1. 10.1016\/j.jpeds.2021.06.048","journal-title":"J Pediatr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000505401","article-title":"Hemolytic uremic syndrome: a contemporary pediatric experience","volume":"144","author":"Alfandary H","year":"2020","unstructured":"Alfandary H, Rinat C, Gurevich E, Eisenstein I, Goldberg O, Kropach N, Landau D. Hemolytic uremic syndrome: a contemporary pediatric experience. Nephron. 2020, 144:109-17. 10.1159\/000505401","journal-title":"Nephron"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi V","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al.. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013, 8:554-62. 10.2215\/CJN.04760512","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931210","article-title":"Anti-factor H antibody and its role in atypical hemolytic uremic syndrome","volume":"13","author":"Raina R","year":"2022","unstructured":"Raina R, Mangat G, Hong G, et al.. Anti-factor H antibody and its role in atypical hemolytic uremic syndrome. Front Immunol. 2022, 13:931210. 10.3389\/fimmu.2022.931210","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.02.012","article-title":"Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19","volume":"201","author":"Turecek PL","year":"2021","unstructured":"Turecek PL, Peck RC, Rangarajan S, et al.. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res. 2021, 201:100-12. 10.1016\/j.thromres.2021.02.012","journal-title":"Thromb Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat C","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, et al.. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016, 31:15-39. 10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00555-6","article-title":"Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future","volume":"25","author":"Gurevich E","year":"2023","unstructured":"Gurevich E, Landau D. Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future. Paediatr Drugs. 2023, 25:193-202. 10.1007\/s40272-022-00555-6","journal-title":"Paediatr Drugs"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2365169","article-title":"Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature","volume":"17","author":"Sep\u00falveda Palamara RA","year":"2024","unstructured":"Sep\u00falveda Palamara RA, Modelli de Andrade LG, Fortunato RM, G\u00f3mez B, Nieto-R\u00edos JF. Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature. Expert Rev Hematol. 2024, 17:361-74. 10.1080\/17474086.2024.2365169","journal-title":"Expert Rev Hematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1404725","article-title":"Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report","volume":"12","author":"Wei X","year":"2024","unstructured":"Wei X, Liu X, Yu Y, et al.. Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report. Front Pediatr. 2024, 12:1404725. 10.3389\/fped.2024.1404725","journal-title":"Front Pediatr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson S","year":"2014","unstructured":"Johnson S, Stojanovic J, Ariceta G, et al.. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol. 2014, 29:1967-78. 10.1007\/s00467-014-2817-4","journal-title":"Pediatr Nephrol"},{"key":"ref31","unstructured":"European Medicines Agency (EMA). Assessment report. Soliris. International non-proprietary name: eculizumab. (2013). https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/soliris-h-c-791-ii-0105-epar-assessment-report-variation_en.pdf."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina EB","year":"2015","unstructured":"Volokhina EB, van de Kar NC, Bergseth G, et al.. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015, 160:237-43. 10.1016\/j.clim.2015.05.018","journal-title":"Clin Immunol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo RA","year":"2009","unstructured":"Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009, 360:544-6. 10.1056\/NEJMc0809959","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger J","year":"2009","unstructured":"N\u00fcrnberger J, Philipp T, Witzke O, et al.. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009, 360:542-4. 10.1056\/NEJMc0808527","journal-title":"N Engl J Med"},{"key":"ref35","unstructured":"Alexion Pharmaceutical, Inc. ULTOMIRIS\u00ae (ravulizumab-cwvz) injection, for intravenous use. (2019). https.\/\/alexion.com\/documents\/ultomiris_uspi."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00858-2","article-title":"Eculizumab treatment for renal failure in a pediatric patient with COVID-19","volume":"33","author":"Mahajan R","year":"2020","unstructured":"Mahajan R, Lipton M, Broglie L, Jain NG, Uy NS. Eculizumab treatment for renal failure in a pediatric patient with COVID-19. J Nephrol. 2020, 33:1373-6. 10.1007\/s40620-020-00858-2","journal-title":"J Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank V","year":"2020","unstructured":"Brocklebank V, Kumar G, Howie AJ, et al.. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int. 2020, 97:1260-74. 10.1016\/j.kint.2020.01.045","journal-title":"Kidney Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan D","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al.. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018, 13:e0195909. 10.1371\/journal.pone.0195909","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau E","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020, 97:1287-96. 10.1016\/j.kint.2020.01.035","journal-title":"Kidney Int"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta G","year":"2021","unstructured":"Ariceta G, Dixon BP, Kim SH, et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2021, 100:225-37. 10.1016\/j.kint.2020.10.046","journal-title":"Kidney Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5414\/CN110516","article-title":"Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data","volume":"97","author":"Tomazos I","year":"2021","unstructured":"Tomazos I, Hatswell AJ, Cataland S, et al.. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clin Nephrol. 2021, 97:261-72. 10.5414\/CN110516","journal-title":"Clin Nephrol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.383968","article-title":"Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat)","volume":"287","author":"Hershko K","year":"2012","unstructured":"Hershko K, Simhadri VL, Blaisdell A, et al.. Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat). J Biol Chem. 2012, 287:44361-71. 10.1074\/jbc.M112.383968","journal-title":"J Biol Chem"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561220.73976.40","article-title":"PF734 patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab","volume":"3","author":"Peipert JD","year":"2019","unstructured":"Peipert JD, Kulasekararaj A, Gaya A, et al.. PF734 patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab. HemaSphere. 2019, 3:321. 10.1097\/01.HS9.0000561220.73976.40","journal-title":"HemaSphere"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01481-6","article-title":"Ravulizumab: a review in atypical haemolytic uraemic syndrome","volume":"81","author":"Syed YY","year":"2021","unstructured":"Syed YY. Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs. 2021, 81:587-94. 10.1007\/s40265-021-01481-6","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299805-exploring-the-intersection-of-atypical-hemolytic-uremic-syndrome-and-substance-use-a-comprehensive-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T18:15:26Z","timestamp":1728324926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299805-exploring-the-intersection-of-atypical-hemolytic-uremic-syndrome-and-substance-use-a-comprehensive-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.71019","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}